Serum concentration of vascular endothelial growth factor of patients with chorioretinal diseases before and after the anti-vascular endothelial growth factor therapy

Serum concentration of vascular endothelial growth factor of patients with chorioretinal diseases before and after the anti-vascular endothelial growth factor therapy - Serum VEGF with chorioretinal diseases before and after the anti-VEGF therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009312

Enrollment

100

Registered

2012-11-11

Start date

2012-11-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic retinopathy, central retinal vein occlusion, branch retinal vein occlusion, age-related macular degeneration, myopic choroidal neovascularization, idiopathic choroidal neovascularization

Interventions

Observation period: 1 month Number of treatment: 1 Amount of treatment and method: intravitreal injection of ranibizumab (0.5mg/0.05ml) or bevacizumab (1.25mg/0.05ml) or aflibercept (2mg/0.05ml)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient with active disease, male or female, people 20 years old or older, with informed concent

Exclusion criteria

Exclusion criteria: Patients without active disease, severe glaucoma, inflammation eye disease, without informed concent

Design outcomes

Primary

Measure	Time frame
The change of the serum concentration of vascular endothelial growth factor before, 1 week,1 month and 2 months after the injection of anti-vascular endothelial growth factor	—

Secondary

Measure	Time frame
The correlation of best corrected visual acuity or central retinal subfield thickness and serum concentration of vascular endothelial growth factor before, 1 week and 1 month after the injection of anti-vascular endothelial growth factor	—

Countries

Japan

Contacts

Public ContactTomoko Sawada

Shiga University of Medical Science Department of Ophthalmology

tsawada@belle.shiga-med.ac.jp077-548-2276

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026